Loading…
Windlas Biotech (WINDLAS)₹974.25−4.34%Pharmaceuticals
At the end of the Jun 2026 quarter, Windlas Biotech's shareholders were: promoters 63.34%, FIIs 2.03%, DIIs 9.86%, public 24.77%. Promoter holding is up 1.41 percentage points from 61.93% a quarter earlier. FII holding is up 0.60 percentage points from 1.43% a year earlier. 0.00% of promoter shares were pledged. It had 44,983 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 62.85% | 62.85% | 62.85% | 62.54% | 62.54% | 62.54% | 62.37% | 62.37% | 62.01% | 62.01% | 61.93% | 63.34% |
| FIIs | 0.80% | 1.34% | 1.17% | 1.58% | 1.99% | 1.54% | 1.51% | 1.43% | 1.10% | 0.93% | 0.60% | 2.03% |
| DIIs | 11.54% | 11.73% | 11.84% | 10.37% | 9.60% | 10.28% | 10.91% | 11.24% | 11.46% | 11.46% | 11.82% | 9.86% |
| Public | 24.81% | 24.08% | 24.14% | 25.51% | 25.87% | 25.64% | 25.21% | 24.96% | 25.43% | 25.60% | 25.65% | 24.77% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 68,779 | 61,883 | 51,263 | 45,811 | 45,693 | 46,577 | 46,370 | 45,874 | 45,420 | 45,448 | 44,756 | 44,983 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited) | Promoter | 40.60% | +0.90 |
| Ashok Kumar Windlass | Promoter | 21.37% | +0.47 |
| Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund | DII | 3.43% | −1.78 |
| Mncl Capital Compounder Fund 2 | DII | 1.71% | +0.52 |
| Bandhan Small Cap Fund | DII | 1.44% | +0.32 |
| Vimla Windlasss | Promoter | 1.39% | +0.03 |
| Ajay Kumar Aggarwal | Public | 1.22% | −0.09 |
| Perpetuity Health To Wealth (H2w) Rising Fund | DII | 1.12% | −0.07 |
| Persistence Capital Fund I | DII | Exited | — |
Promoters held 63.34% of Windlas Biotech at the end of the Jun 2026 quarter, up 0.97 percentage points from 62.37% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 2.03% (up 1.43 percentage points from 0.60% a quarter earlier) and domestic institutions (DIIs) held 9.86% (down 1.96 percentage points from 11.82% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
Windlas Biotech had 44,983 shareholders at the end of the Jun 2026 quarter, against 45,874 a year earlier.
Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund (DII) held 3.43% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.